{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:11:10Z","timestamp":1773364270572,"version":"3.50.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.cca.2019.01.013","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T20:42:28Z","timestamp":1547671348000},"page":"52-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Plasminogen activator inhibitor 1 in acute coronary syndromes"],"prefix":"10.1016","volume":"491","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-2774","authenticated-orcid":false,"given":"Marin","family":"Pavlov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-5777","authenticated-orcid":false,"given":"Ivana","family":"\u0106elap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.cca.2019.01.013_bb0005","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(01)00293-6","article-title":"Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001","volume":"103","author":"Huber","year":"2001","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cca.2019.01.013_bb0010","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.1074\/jbc.M611642200","article-title":"Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor","volume":"282","author":"Gorlatova","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2019.01.013_bb0015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.02.135","article-title":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","volume":"164","author":"Jung","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cca.2019.01.013_bb0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1011955018052","article-title":"Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease","volume":"11","author":"Huber","year":"2001","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.cca.2019.01.013_bb0025","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2004-04-1439","article-title":"Platelets synthesize large amounts of active plasminogen activator inhibitor 1","volume":"104","author":"Brogren","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cca.2019.01.013_bb0030","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2007-978677","article-title":"Fat cell function and fibrinolysis","volume":"32","author":"Alessi","year":"2000","journal-title":"Horm. Metab. Res."},{"issue":"2016","key":"10.1016\/j.cca.2019.01.013_bb0035","first-page":"267","volume":"37","author":"Roffi","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2019.01.013_bb0040","volume":"2017","author":"Ibanez","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2019.01.013_bb0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.11613\/BM.2013.031","article-title":"Croatian society of medical biochemistry and laboratory medicine: national recommendations for venous blood sampling","volume":"23","author":"Nikolac","year":"2013","journal-title":"Biochem. Med. (Zagreb)"},{"key":"10.1016\/j.cca.2019.01.013_bb0050","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12959-016-0123-z","article-title":"Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories","volume":"14","author":"Magnette","year":"2016","journal-title":"Thromb. J."},{"key":"10.1016\/j.cca.2019.01.013_bb0055","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1538-7836.2007.02401.x","article-title":"Preanalytical conditions that affect coagulation testing, including hormonal status and therapy","volume":"5","author":"Blomback","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0060","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1160\/TH16-07-0572","article-title":"Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation","volume":"117","author":"Iwaki","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0065","series-title":"Criteria and Search for Specific Assays for Active Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma","author":"Kluft","year":"2000"},{"key":"10.1016\/j.cca.2019.01.013_bb0070","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2516.2008.01834.x","article-title":"Plasminogen activator inhibitor type 1 deficiency","volume":"14","author":"Mehta","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.cca.2019.01.013_bb0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1055\/s-0029-1214155","article-title":"Biological variation in tests of hemostasis","volume":"35","author":"Banfi","year":"2009","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0080","series-title":"A Common Calibrator Does Not Secure Harmonisation of Commercial T-PA and PAI-1 Antigen Measurements","first-page":"39","volume":"Vol. 13","author":"de Maat","year":"2001"},{"key":"10.1016\/j.cca.2019.01.013_bb0085","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.clinbiochem.2017.08.015","article-title":"The investigation of interferences in immunoassay","volume":"50","author":"Ward","year":"2017","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2019.01.013_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0165-022X(00)00103-2","article-title":"Measuring plasminogen activator inhibitor activity in plasma by two enzymatic assays","volume":"45","author":"Chiu","year":"2000","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.cca.2019.01.013_bb0095","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1182\/blood.V84.4.1164.1164","article-title":"Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin","volume":"84","author":"Patston","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.cca.2019.01.013_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2796.2005.01507.x","article-title":"Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction","volume":"258","author":"Lundblad","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2019.01.013_bb0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1055\/s-0038-1645042","article-title":"Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis","volume":"63","author":"Huber","year":"1990","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0110","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1161\/01.CIR.91.2.284","article-title":"Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Atherosclerosis risk in communities study","volume":"91","author":"Salomaa","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0268-9499(08)80100-2","article-title":"Tissue-type plasminogen activator and Type-1 plasminogen activator inhibitor in patients with coronary artery disease \u2014 Relations to clinical variables and cardiovascular risk factors","volume":"9","author":"Geppert","year":"1995","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.cca.2019.01.013_bb0120","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1681\/ASN.V1261255","article-title":"Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis","volume":"12","author":"Segarra","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2019.01.013_bb0125","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/01.CIR.94.9.2057","article-title":"Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities","volume":"94","author":"Juhan-Vague","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0130","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2010-01-263103","article-title":"Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men","volume":"116","author":"Meltzer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cca.2019.01.013_bb0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.ATV.21.4.611","article-title":"Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study","volume":"21","author":"Folsom","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2019.01.013_bb0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.02.002","article-title":"Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham Heart Study","volume":"140","author":"Tofler","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cca.2019.01.013_bb0145","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM200006153422406","article-title":"Plasminogen-activator inhibitor type 1 and coronary artery disease","volume":"342","author":"Kohler","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2019.01.013_bb0150","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1161\/01.CIR.96.9.3180","article-title":"Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice","volume":"96","author":"Carmeliet","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0155","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/383441a0","article-title":"The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin","volume":"383","author":"Stefansson","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.cca.2019.01.013_bb0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(87)93050-9","article-title":"Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction","volume":"2","author":"Hamsten","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2019.01.013_bb0165","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/0735-1097(94)90002-7","article-title":"Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age","volume":"24","author":"Malmberg","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2019.01.013_bb0170","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/hrt.80.4.334","article-title":"von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction","volume":"80","author":"Jansson","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.cca.2019.01.013_bb0175","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/hrt.70.6.530","article-title":"Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?","volume":"70","author":"Gray","year":"1993","journal-title":"Br. Heart J."},{"key":"10.1016\/j.cca.2019.01.013_bb0180","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0037-1615382","article-title":"Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction","volume":"80","author":"Nordt","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0185","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1055\/s-0038-1648134","article-title":"Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction","volume":"65","author":"Sane","year":"1991","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000083471.33820.3C","article-title":"Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality","volume":"108","author":"Collet","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1536\/ihj.50.33","article-title":"Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission","volume":"50","author":"Akkus","year":"2009","journal-title":"Int. Heart J."},{"key":"10.1016\/j.cca.2019.01.013_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0167-5273(02)00186-9","article-title":"Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death","volume":"85","author":"Soeki","year":"2002","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.cca.2019.01.013_bb0205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s102380100006","article-title":"D-dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study","volume":"1","author":"Prisco","year":"2001","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.cca.2019.01.013_bb0210","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1161\/01.CIR.103.25.3062","article-title":"Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina","volume":"103","author":"Bogaty","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0215","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1055\/s-0037-1613477","article-title":"Evidence of prolonged disturbances in the haemostatic, hemorheologic and inflammatory profiles in transmural myocardial infarction survivors","volume":"89","author":"Sargento","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0220","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3325\/cmj.2018.59.108","article-title":"Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study","volume":"59","author":"Pavlov","year":"2018","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.cca.2019.01.013_bb0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.thromres.2004.06.040","article-title":"Risk stratification in patients with unstable angina and\/or non-ST-elevation myocardial infarction by troponin T and plasminogen-activator-inhibitor-1 (PAI-1)","volume":"114","author":"Sinkovic","year":"2004","journal-title":"Thromb. Res."},{"key":"10.1016\/j.cca.2019.01.013_bb0230","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000137700","article-title":"The relationship of plasminogen activator inhibitor-1 levels to the ST deviation pattern of acute myocardial infarction","volume":"112","author":"Rott","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.cca.2019.01.013_bb0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-018-0166-4","article-title":"Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis","volume":"16","author":"Jung","year":"2018","journal-title":"Thromb. J."},{"key":"10.1016\/j.cca.2019.01.013_bb0240","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0735-1097(95)00210-U","article-title":"Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage","volume":"26","author":"Haider","year":"1995","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.cca.2019.01.013_bb0245","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1160\/TH06-11-0621","article-title":"Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction","volume":"98","author":"Huisse","year":"2007","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0250","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/hc3301.092803","article-title":"Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition","volume":"104","author":"Kaikita","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0255","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0002-9440(10)63135-5","article-title":"Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction","volume":"164","author":"Takeshita","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cca.2019.01.013_bb0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-0036-1586228","article-title":"The role of plasminogen activator inhibitor type-1 in fibrosis","volume":"43","author":"Flevaris","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.cca.2019.01.013_bb0265","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00418-007-0300-z","article-title":"Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants","volume":"128","author":"Zaman","year":"2007","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.cca.2019.01.013_bb0270","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1161\/01.ATV.0000181762.31694.da","article-title":"Assessment of hemostatic risk factors in predicting arterial thrombotic events","volume":"25","author":"Feinbloom","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2019.01.013_bb0275","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/jcmm.12875","article-title":"A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase","volume":"20","author":"Gong","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cca.2019.01.013_bb0280","first-page":"147","article-title":"PAI-1 Inhibition - another therapeutic option for cardiovascular protection","volume":"10","author":"Baluta","year":"2015","journal-title":"Maedica"},{"key":"10.1016\/j.cca.2019.01.013_bb0285","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1253\/jcj.61.308","article-title":"Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction","volume":"61","author":"Moriyama","year":"1997","journal-title":"Jpn. Circ. J."},{"key":"10.1016\/j.cca.2019.01.013_bb0290","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1161\/01.HYP.0000040264.15961.48","article-title":"ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time","volume":"40","author":"Brown","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.cca.2019.01.013_bb0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09291010600906133","article-title":"Hemostatic triggers of myocardial infarction","volume":"38","author":"Haus","year":"2007","journal-title":"Biol. Rhythm. Res."},{"key":"10.1016\/j.cca.2019.01.013_bb0300","doi-asserted-by":"crossref","first-page":"359","DOI":"10.5665\/sleep.3414","article-title":"Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea","volume":"37","author":"Bagai","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.cca.2019.01.013_bb0305","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/07420529109059170","article-title":"Circadian variation of fibrinolytic activity in blood","volume":"8","author":"Andreotti","year":"1991","journal-title":"Chronobiol. Int."},{"key":"10.1016\/j.cca.2019.01.013_bb0310","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2013-07-517060","article-title":"Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep\/wake cycle","volume":"123","author":"Scheer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cca.2019.01.013_bb0315","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2013-11-538330","article-title":"PAI at breakfast (whether you like it or not)","volume":"123","author":"Young","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cca.2019.01.013_bb0320","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.510310214","article-title":"Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices","volume":"31","author":"Piscaglia","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cca.2019.01.013_bb0325","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/000331979304400701","article-title":"The clinical outcome of acute myocardial infarction is related to the circadian rhythm of myocardial infarction onset","volume":"44","author":"Hansen","year":"1993","journal-title":"Angiology"},{"key":"10.1016\/j.cca.2019.01.013_bb0330","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1161\/CIRCOUTCOMES.109.913343","article-title":"Circadian rhythms in patients with ST-elevation myocardial infarction","volume":"3","author":"Holmes","year":"2010","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.cca.2019.01.013_bb0335","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/01.CIR.99.19.2517","article-title":"Thrombogenic factors and recurrent coronary events","volume":"99","author":"Moss","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2019.01.013_bb0340","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/01.ATV.20.8.2019","article-title":"Plasma levels of tissue plasminogen activator\/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study","volume":"20","author":"Wiman","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.cca.2019.01.013_bb0345","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000065080","article-title":"Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction","volume":"32","author":"Ganti","year":"2002","journal-title":"Pathophysiol. Haemost. Thromb."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119300269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119300269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:47:20Z","timestamp":1757861240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119300269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":69,"alternative-id":["S0009898119300269"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.01.013","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasminogen activator inhibitor 1 in acute coronary syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}